NYSE:AMPE Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AMPE Stock Alerts $0.92 +0.11 (+13.50%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.9550-Day Range$0.81▼$2.3052-Week Range$0.70▼$8.30Volume56,844 shsAverage Volume178,079 shsMarket Capitalization$767,750.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Ampio Pharmaceuticals alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Ampio Pharmaceuticals Stock (NYSE:AMPE)Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Read More AMPE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPE Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSE:AMPE)March 27, 2024 | investorplace.comAMPE Stock Earnings: Ampio Pharmaceuticals Reported Results for Q4 2023March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 26, 2024 | money.usnews.comAmpio Pharmaceuticals IncMarch 26, 2024 | finanznachrichten.deAmpio Pharmaceuticals, Inc.: Ampio Announces Voluntary Delisting and SEC DeregistrationMarch 26, 2024 | msn.comUS Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence ReadingsMarch 25, 2024 | finance.yahoo.comAmpio Announces Voluntary Delisting and SEC DeregistrationMarch 20, 2024 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2024 | WealthPress (Ad)The ProTrader Dashboard is simple to use! (trade demo inside)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.February 29, 2024 | msn.comAmpio Pharmaceuticals, Ironwood, Incannex among healthcare moversFebruary 15, 2024 | finanznachrichten.deAmpio Pharmaceuticals, Inc.: Ampio Provides Update on Results from Pre-IND Enabling StudiesFebruary 14, 2024 | prnewswire.comAmpio Provides Update on Results from Pre-IND Enabling StudiesJanuary 26, 2024 | msn.comAmpio Pharmaceuticals Announces At-The-Market Stock OfferingDecember 28, 2023 | seekingalpha.comSociedad Quimica Y Minera de Chile, Altice USA, Cingulate among premarket gainers' packDecember 1, 2023 | msn.comWhat's Going On With Ampio Pharmaceuticals Stock?December 1, 2023 | msn.comRedhill Biopharma, Ampio Pharmaceuticals among healthcare moversNovember 30, 2023 | benzinga.comThinking about buying stock in Aditxt Inc, Ampio Pharmaceuticals, TOP SHIPS, Mullen Automotive, or Oatly GroupOctober 5, 2023 | finance.yahoo.comAmpio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201October 4, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference 63 Day 2 on October 5 Register NowSeptember 26, 2023 | finance.yahoo.comAmpio Pharmaceuticals to Present at the Emerging Growth ConferenceSeptember 7, 2023 | thestreet.comAmpio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach Primary EndpointAugust 31, 2023 | seekingalpha.comAmpio Pharmaceuticals announces 20-to-1 reverse stock splitAugust 31, 2023 | markets.businessinsider.comAmpio Pharmaceuticals Board Approves Reverse Stock Split - Quick FactsAugust 31, 2023 | finance.yahoo.comAmpio Pharmaceuticals Announces Reverse Stock SplitAugust 3, 2023 | benzinga.comThinking about buying stock in Wavedancer, Urogen Pharma, Ampio Pharmaceuticals, Innoviz Technologies, or Rigetti Computing?June 22, 2023 | msn.com3 Biotech Stocks to Buy With Explosive Upside PotentialJune 3, 2023 | finance.yahoo.comAMPE - Ampio Pharmaceuticals, Inc.See More Headlines Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/29/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:AMPE CUSIPN/A CIK1411906 Webampiopharma.com Phone720-437-6500Fax720-437-6501Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.36% Return on Assets-85.59% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.62 per share Price / Book0.06Miscellaneous Outstanding Shares830,000Free Float805,000Market Cap$767,750.00 OptionableNo Data Beta2.00 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Michael A. Martino (Age 67)CEO & Director Comp: $548.14kDr. David Bar-Or M.D. (Age 75)Founder & Chairman of Scientific Advisory Board Comp: $145.6kMr. Daniel G. Stokely CPA (Age 60)CFO, Corporate Secretary & Treasurer Comp: $346.73kApril RamirezClinical Trial ManagerKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCAditxtNASDAQ:ADTXBellerophon TherapeuticsNASDAQ:BLPHNovaBay PharmaceuticalsNYSE:NBYEvelo BiosciencesNASDAQ:EVLOView All CompetitorsInsidersJ Kevin BuchiBought 1,250 shares on 6/8/2023Total: $7,500.00 ($6.00/share)Michael A MartinoBought 3,844 shares on 5/24/2023Total: $22,295.20 ($5.80/share)David R StevensBought 2,500 shares on 5/11/2023Total: $11,000.00 ($4.40/share)View All Insider Transactions AMPE Stock Analysis - Frequently Asked Questions How have AMPE shares performed in 2024? Ampio Pharmaceuticals' stock was trading at $2.05 at the start of the year. Since then, AMPE stock has decreased by 54.9% and is now trading at $0.9250. View the best growth stocks for 2024 here. When is Ampio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AMPE earnings forecast. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSE:AMPE) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). When did Ampio Pharmaceuticals' stock split? Ampio Pharmaceuticals's stock reverse split before market open on Tuesday, September 12th 2023. The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Tesla (TSLA), Agenus (AGEN) and American Airlines Group (AAL). Who are Ampio Pharmaceuticals' major shareholders? Ampio Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Dan Stokely, David R Stevens, Holli Cherevka, J Kevin Buchi, Michael A Martino and Philip H Coelho. View institutional ownership trends. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AMPE) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.